Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
Authors:
- 29 August 2022
- journal article
- research article
- Published by Elsevier in Clinical Immunology
- Vol. 244, 109103
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Beijing Municipality (L202038)
- National Natural Science Foundation of China (81773494)
- National Natural Science Foundation of China (82273692)
- National Natural Science Foundation of China (81621005)
This publication has 43 references indexed in Scilit:
- Correlates of protection against SARS-CoV-2 in rhesus macaquesNature, 2020
- Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humansScience, 2020
- Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assayNature Protocols, 2020
- Lessons for COVID-19 Immunity from Other Coronavirus InfectionsImmunity, 2020
- SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19Nature, 2020
- SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controlsNature, 2020
- Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed IndividualsCell, 2020
- Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological StudiesViruses, 2020
- Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2Emerging Microbes & Infections, 2020
- Analysis of antigen-specific T-cell responses with synthetic peptides—what kind of peptide for which purpose?Human Immunology, 2004